XOMA Royalty Corp.

NASDAQ:XOMA

Biotechnology

Healthcare
$40.17 +0.44%

+$0.19 today

Market cap
$503.77M
Beta
0.87
P/E (TTM)
15.8
EPS (TTM)
$2.65
52W Low $22.29High $42.81

Volume 4.22M

Average 0.21M

Returns on capital

XOMA Royalty Corp. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

30.5%

avg 105.7%

ROIC

4.5%

avg -47.2%

ROA

11.6%

avg -19.0%

Analysis

ROE is currently the strongest return metric at 30.5% versus its period average of 105.7%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Owen Hughes Jr.

Chief Executive Officer & DirectorUSD 1.14M51——

Brad Sitko

Chief Investment OfficerUSD 853.5K45——

Juliane Snowden

Head of Investor Relations————

Jeffrey Trigilio

Chief Financial Officer—42103.91K0.83%

Maricel Perea Montano

Chief Legal Officer & Corporate Secretary——37.07K0.30%

Compensation is shown in the reported currency; data updated Jun 18, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 20, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$2.50M

Sells

0

$0.00

Net Transaction Value

+$2.50M

Net buying

Most Active

Hughes Owen

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Dec 4, 25

Hughes Owen

Direct

Buy$2.5M

Summary

Insiders reported 1 buys worth $2.50M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.50M. Hughes Owen was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
-3.1% (5yr)1 analysts
RevenueN/AN/A+105.3%
+8.8% (5yr)1 analysts
Net IncomeN/AN/AN/A
-6.7% (5yr)1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +105.3% over three years. Forward estimates point to Revenue at +8.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does XOMA Royalty Corp. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about XOMA's management, answered from reported figures.

Who manages XOMA?

XOMA Royalty Corp. (XOMA) lists 5 active executives. The top listed executive is Brad Sitko, Chief Investment Officer.

Are XOMA insiders buying or selling?

Recent insider activity shows net buying of $1.87M.